Available CD19 chimeric antigen receptor (CAR) T-cells show activity in relapsed lymphoma, but long-lasting complete response rates remain below 40%. PD-L1 upregulation, that results in T-cell exhaustion, and CD19 antigen loss are thought to play a role in relapse.
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received…
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology,…
Here we summarize the results from the VENICE-1 trial evaluating venetoclax monotherapy in patients with R/R CLL, published by Kater et al.1 in Lancet Oncology.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US.…
Here, we summarize results from a phase Ib/II trial assessing the safety and efficacy of polatuzumab vedotin in combination with rituximab and lenalidomide in patients…
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously…
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and…
On March 14, 2024, the U.S. FDA approved lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R CLL/SLL.
